GeorgePapakostasMD

Psychiatry • Boston, MA

Professor at Harvard Medical School and Associate Executive Director, Clinical Trials Network and Institute, Massachusetts General Hospital.

Join to view full profile

Dr. Papakostas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Papakostas' full profile

Already have an account?

Office
55 Fruit St
S50 4 Massachusetts General Hospital
Boston, MA 02114
Phone+1 617-726-6697

Fax+1 617-726-2894

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1999 - 2002
Steward Carney HospitalInternship, Internal Medicine, 1998 - 1999
New York University School of MedicineClass of 1998

Certifications & Licensure

MA State Medical License 2002 - 2026
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression Start of enrollment: 2004 May 01
Completed
Phase 2
A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD) Start of enrollment: 2006 Nov 01
Completed
Phase 4
A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder Start of enrollment: 2008 Mar 01
Completed
Phase 2
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs Start of enrollment: 2008 Jul 01
Completed
Phase 2
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder Start of enrollment: 2008 Apr 01
Completed
Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder Start of enrollment: 2009 Jul 01
Completed
Phase 4
Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose Start of enrollment: 2011 Sep 01
Completed
Phase 3
Major Depressive Disorder With Mixed Features - Extension Start of enrollment: 2011 Sep 01
Completed
Phase 3
Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

211 citations
Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating M...
George I. Papakostas, Michael E. Thase, Maurizio Fava, J. Craig Nelson, Richard C. Shelton
Biological Psychiatry. 2007-12-01
302 citations
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Roger S. McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff, Gerard Sanacora, James W. Murrough
The American Journal of Psychiatry. 2021-03-17
18 citations
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized dou...
Anna Feeney, Rebecca S. Hock, Marlene P. Freeman, Martina Flynn, Bettina B. Hoeppner
European Neuropsychopharmacology. 2021-06-02

Journal Articles

Research Paper Tachyphylaxis in Major Depressive Disorder: A Review of the Current State of Research
Gustavo Kinrys, Andrew A Nierenberg, George I Papakostas, David Mischoulon, Maurizio Fava, Marlene P Freeman, ScienceDirect
Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)
Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature

Lectures

Therapeutic Augmentation for Treatment-Resistant MDD
162nd Annual Meeting, San Francisco, California, USA
Therapeutic Augmentation for Treatment-Resistant MDD
American Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA

Press Mentions

4 Serotonin Supplements to Treat Depression, Anxiety, & Insomnia YourselfJune 5th, 2019
Allergan’s Phase III Botox Trial for Depression Pushed to H2 2019December 10th, 2018
Major Depression ZiprasidoneOctober 6th, 2017
Join now to see all

Grant Support

1/2-Ziprasidone Augmentation Of Ssris For Treatment-Resistant Depression (TRD)National Institute Of Mental Health2008–2012
S-Adenosyl Methionine(Same)Augmentation Of Ssris In MDDNational Institute Of Mental Health2004–2008